BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38386926)

  • 21. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of mTOR As an Essential Kinase in SCLC.
    Kern JA; Kim J; Foster DG; Mishra R; Gardner EE; Poirier JT; Rivard C; Yu H; Finigan JH; Dowlati A; Rudin CM; Tan AC
    J Thorac Oncol; 2020 Sep; 15(9):1522-1534. PubMed ID: 32599072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
    Qiu Z; Lin A; Li K; Lin W; Wang Q; Wei T; Zhu W; Luo P; Zhang J
    Drug Des Devel Ther; 2019; 13():2021-2041. PubMed ID: 31417239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
    Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
    Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breaking the vicious circle: Extrachromosomal circular DNA as an emerging player in tumour evolution.
    Robert M; Crasta K
    Semin Cell Dev Biol; 2022 Mar; 123():140-150. PubMed ID: 34857471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extrachromosomal DNA in the cancerous transformation of Barrett's oesophagus.
    Luebeck J; Ng AWT; Galipeau PC; Li X; Sanchez CA; Katz-Summercorn AC; Kim H; Jammula S; He Y; Lippman SM; Verhaak RGW; Maley CC; Alexandrov LB; Reid BJ; Fitzgerald RC; Paulson TG; Chang HY; Wu S; Bafna V; Mischel PS
    Nature; 2023 Apr; 616(7958):798-805. PubMed ID: 37046089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
    Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V;
    Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer.
    Yi E; Gujar AD; Guthrie M; Kim H; Zhao D; Johnson KC; Amin SB; Costa ML; Yu Q; Das S; Jillette N; Clow PA; Cheng AW; Verhaak RGW
    Cancer Discov; 2022 Feb; 12(2):468-483. PubMed ID: 34819316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates.
    Anderson WC; Boyd MB; Aguilar J; Pickell B; Laysang A; Pysz MA; Bheddah S; Ramoth J; Slingerland BC; Dylla SJ; Rubio ER
    PLoS One; 2015; 10(5):e0125255. PubMed ID: 25955027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
    Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
    Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topotecan in the treatment of recurrent small cell lung cancer: an update.
    Ardizzoni A
    Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topotecan in the treatment of relapsed small cell lung cancer.
    Quoix E
    Onco Targets Ther; 2008 Dec; 1():79-86. PubMed ID: 21127755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circlehunter: a tool to identify extrachromosomal circular DNA from ATAC-Seq data.
    Yang M; Zhang S; Jiang R; Chen S; Huang M
    Oncogenesis; 2023 May; 12(1):28. PubMed ID: 37217468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.
    Kim YH; Girard L; Giacomini CP; Wang P; Hernandez-Boussard T; Tibshirani R; Minna JD; Pollack JR
    Oncogene; 2006 Jan; 25(1):130-8. PubMed ID: 16116477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase separation of ecDNA aggregates establishes
    Conte M; Matteuzzi T; Esposito A; Chiariello AM; Bianco S; Vercellone F; Nicodemi M
    bioRxiv; 2023 Jul; ():. PubMed ID: 37503084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
    Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
    Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topotecan: a review of its efficacy in small cell lung cancer.
    Ormrod D; Spencer CM
    Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
    Perez-Soler R; Glisson BS; Lee JS; Fossella FV; Murphy WK; Shin DM; Hong WK
    J Clin Oncol; 1996 Oct; 14(10):2785-90. PubMed ID: 8874340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Lee MS; Jung K; Song JY; Sung MJ; Ahn SB; Lee B; Oh DY; Choi YL
    Mol Ther Oncolytics; 2020 Mar; 16():188-196. PubMed ID: 32099898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.